Chen Yuanyuan, Ye Xin, Wang Jie, Han Baosan
Department of Breast, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
Department of Breast, Xinhua Hospital, Affiliated with Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
J Cancer Res Ther. 2025 May 1;21(2):425-434. doi: 10.4103/jcrt.jcrt_277_24. Epub 2025 May 2.
This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.
Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.
Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).
The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.
本回顾性研究旨在探讨HER2低表达和零表达的非特殊类型浸润性乳腺癌(IBC-NST)的临床病理特征、治疗方法、预后差异及影响因素。
从上海交通大学乳腺癌数据库中获取2009年7月至2019年12月期间HER2低表达和零表达的IBC-NST患者的临床资料。采用Kaplan-Meier法、对数秩检验和Cox回归分析。
在2071例IBC-NST患者中,1618例(78.1%)HER2低表达,453例(21.9%)HER2零表达。HER2零表达组中年龄低于40岁、Ki67>20%和肿瘤分级为III级的患者比例较高。HER2低表达组中雌激素受体阳性、孕激素受体阳性、激素受体(HR)阳性及接受内分泌治疗的比例较高。两组间无乳腺癌生存间隔(BCFI)和总生存期(OS)相似。在HR阳性亚组中,临床病理特征、治疗类型、BCFI和OS均无显著差异。在HR阴性亚组中,HER2低表达组中年龄超过40岁和绝经后患者的比例较高。多因素分析显示,无论HER2状态如何,淋巴结分期(N2-N3)是BCFI和OS的独立危险因素。同时,HER2低表达是HR阴性亚组中BCFI的独立危险因素(风险比,1.781;95%置信区间,1.061-2.989;P=0.029)。
HER2低表达IBC-NST的临床生物学特征可能受HR状态影响。在相同HR状态下,HER2低表达和HER2零表达IBC-NST的临床病理特征和预后相当。